Kalin specializes in providing strategic HEOR and commercial support for pre-commercial assets, including: market assessments, prioritizations, and evidence planning, as well as early-to-late stage asset evaluations for biopharma clients of all sizes. Kalin was instrumental in the development of Trinity’s HEOR Center of Excellence, supporting clients on value proposition development and strategic evidence generation planning and execution. Kalin has a depth of knowledge in several therapeutic areas including: CNS, Women’s Health, rare disease, immunology, and oncology.

Kalin has a BA from Colgate University and a Master’s in Public Health from Columbia University with a concentration in Epidemiology and Comparative Effectiveness and Outcomes Research.